around 4 1/2 on nasdaq:
(COMTEX) B: CRYO-CELL Achieves Record Monthly Sales For Its U-Cord(TM
B: CRYO-CELL Achieves Record Monthly Sales For Its U-Cord(TM) Preservation
Program
CLEARWATER, Fla., Nov 3, 2000 /PRNewswire via COMTEX/ -- Wanda D. Dearth,
President & Chief Operating Officer of CRYO-CELL International, Inc. (Nasdaq:
CCEL), announced today that the Company achieved record sales during October for
the Company's umbilical cord (U-Cord)(TM) stem cell preservation program.
Monthly sales exceeded $200,000, which compares to $109,712 during October 1999,
representing an increase of over 80%. Also during the month, requests for
information increased 32% and clients who paid to enroll in our Program
increased almost 20% over the previous month.
Ms. Dearth commented, "It is extremely gratifying to see the results of the
growth initiatives we have put in place, including the addition of field- based
Clinical Educators calling on hospitals, doctors offices and childbirth
educators." The Company is also reaping the benefits of its investments in a
variety of awareness programs, including Internet links with iVillage.com,
babygear.com, HomePharmacy.com, and Lamaze.com. As a result of accelerating
growth, the Clinical Support function has been supplemented with 24/7 RN
coverage, which now provides the finest service to both clients and medical
caregivers.
The Company believes that the growth in revenues has positioned CRYO-CELL well
to continue as America's fastest growing U-Cord stem cell preservation firm.
According to Daniel D. Richard, Chief Executive Officer, "It is exciting to see
the participation of greater than 8500 OB/GYNs in supporting their patients'
decisions to preserve their newborn's cord blood. We expect this number to
increase even more as CD-ROMs are distributed during November to 40,000 ACOG
(American College of Obstetricians and Gynecologists) members in which CRYO-CELL
is the exclusive cord blood preservation program."
CRYO-CELL pioneered America's most affordable cord blood stem cell processing
and storage service. The initial fee of $275 includes the specimen collection
kit, processing, testing and first year's storage. The annual storage fee
thereafter is fixed at $50 for specimens already stored. The Company has become
the largest exclusive computerized, robotically operated U- Cord(TM) stem cell
repository, which cryopreserves cord blood only for the potential medical
benefit of newborns and/or their siblings.
CRYO-CELL Receives $600,000 Final Payment for European Marketing Rights
Mr. Richard also announced that the $600,000 balance of the $1.4 million payment
for the European marketing rights has been received. This completes the initial
payment obligation. CRYO-CELL will also receive entitlements from processing
fees and a minimum of 18% of annual storage fees from European operations.
Forward Looking Statement
Statements wherein the terms "believes," "intends," or "expects," as used are
intended to reflect "forward-looking statements" of the Company. The information
contained herein is subject to various risks, uncertainties and other factors
that could cause actual results to differ materially from the results
anticipated in such forward-looking statements or paragraphs. Readers should
carefully review the risk factors described in other documents the Company files
from time to time with the Securities and Exchange Commission, including the
most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any
Current Reports on Form 8-K filed by the Company.
SOURCE CRYO-CELL International, Inc.
CONTACT: Sharon Will of Saggi Capital Corp., 212-572-0762, or fax,
212-572-0764, for CRYO-CELL International
URL: cryo-cell.com
prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: Florida
INDUSTRY KEYWORD: MTC
BIO
SUBJECT CODE: SLS
OTC
*** end of story *** |
